International Journal of Pharmaceutical Research and Applications
Volume 8, Issue 4 July-Aug 2023, pp: 2552-2557 www.ijprajournal.com ISSN: 2249-7781

# A Review on Hypertension

Prajapati Ekta*[1], Thapa Tanisha*[1]
[1]*Pharmacy, Oriental University, Indore, M.P., India*
[2]*Pharmacy, Modern Institute of Pharmaceutical Sciences, Indore, M.P., India*

Submitted: 20-08-2023 Accepted: 31-08-2023

**ABSTRACT**
People are now experiencing high blood pressure because of the oviduct. The most potent, modifiable risk factor for the onset of heart failure may be hypertension.2019's COVID19 left most people with hypertension-related problems. Some in-depth research has suggested a link between oviduct 19 vulnerability and the renin-angiotensin-aldosterone system. After contracting the corona virus 2 (cov-2) that causes severe acute respiratory syndrome, a variety of organs exhibit symptoms.Low blood oxygen levels (hypoxia), shortness of breath, and a decrease in sugar levels (anomia) are the major symptoms.People are now experiencing high blood pressure because of the oviduct. The most potent, modifiable risk factor for the onset of heart failure may be hypertension.2019's COVID19 left most people with hypertension-related problems. Some in-depth research has suggested a link between oviduct 19 vulnerability and the renin-angiotensin-aldosterone system. After contracting the corona virus 2 (cov-2) that causes severe acute respiratory syndrome, a variety of organs exhibit symptoms.Low blood oxygen levels (hypoxia), shortness of breath, and a decrease in sugar levels (anomia) are the major symptoms.People are now experiencing high blood pressure because of the oviduct. After contracting the corona virus 2 (cov-2) that causes severe acute respiratory syndrome, a variety of organs exhibit symptoms.Low blood oxygen levels (hypoxia), shortness of breath, and a decrease in sugar levels (anomia) are the major symptoms.People are now experiencing high blood pressure because of the oviduct. After contracting the corona virus 2 (cov-2) that causes severe acute respiratory syndrome, a variety of organs exhibit symptoms.

**Key words**: - Hypertension, renin-angiotensin-aldosterone system, Cov-2, hypoxia, heart failure, anemia.

## I. INTRODUCTION

High blood pressure, often known as hypertension, is a fairly prevalent illness that increases the risk of cardiac arrest as well as severe hazards to the brain, kidneys, and other organs. Cardiovascular mortality and morbidity make up the risk factor. The distinction between normotensives and hypertensives in a manometric cutoff reading is arbitrary.Because you are unaware of what is wrong with your body, high blood pressure is often known as the "silent killer".According to the j nc 7* (joint national committee)(2003) and who-is-h standards, the normal blood pressure level is defined as having a systolic pressure of 140 mm Hg and a diastolic pressure of 90 mm Hg.

**Three categories of hypertension were established.**

| | |
|---|---|
| **Stage 1** | **That is mild hypertension blood pressure level :130-139/or diastolic between80-89mmhg.** |
| **Stage 2** | **Moderate hypertensive blood pressure level :140/90 mmhg orhigher.** |
| **Stage 3** | **Crisis hypertensive (get emergency care) blood pressure level :180/120 mmhg orhigher.** |
| | **For the treatment of hypertensive go for the anti hypertensive drugs that are diureticsand manyother.** |

**Figure No. 01**

As oviduct 19 opened in (2019), the prevalence of hypertension increased. This was a pandemic issue since the severe respiratory syndrome coronavirus 2 (SARS-CoV-2) is the cause of the acute respiratory viral illness. Over 200 countries and territories throughout the world

International Journal of Pharmaceutical Research and Applications
Volume 8, Issue 4 July-Aug 2023, pp: 2552-2557 www.ijprajournal.com ISSN: 2249-7781

have been impacted by this, which has spread quickly throughout China and the rest of the world.120 million cases of cases were reported worldwide as of March 22, 2021, with 2,7,11,071 deaths.There are 537,781 deaths and 29,497,998 cases, respectively, in the united states alone. This was spread very easily by faeces, droplets, and contact with the surface where the virus is present. Due to this, a significant portion of oviduct 19 patients exhibit mild to moderate sickness; 15% of elderly persons or those with chronic diseases may proceed toacute respiratory distress syndrome (ARDS), septic shocks, and multiple organ failure can result from severe pneumonia. According to epidemiological research, hypertension is the most common disease.Social isolation, masking, and hand sanitization were strongly advised as ways to lessen the chance of contracting SARS-CoV-2 because there were no effective vaccinations or treatments available during the earliest stages of the disease. Despite the fact that these precautions assisted in shielding people from the virus, the literature contends that COVID-19's quick spread and the lockdowns severely constrained access to medical care and disrupted medical supply networks. In May 2020, the number of outpatient visits declined by 22%, and the number of outpatient prescriptions, including calcium channel blockers and other common drugs, also decreased, according to a study involving over 800,000 participants in 26 hospitals in Japan, which by May 2020 had fallen by 20%.

## HYPER TENSIONEPIDEMIOLOGY

The prevalence of hypertension in U.S. adults has continued to increase. In 2018, the American Heart Association (AHA) heart disease and stroke statistics update reported that about 34% of U.S. adults had hypertension, using diagnostic SBP/DBP threshold of 140/90 mm Hg (Benjamin 2018). However, the American College of Cardiology and AHA (ACC/AHA) 2017 blood pressure guidelines lowered the threshold for the diagnosis of hypertension to an SBP/DBP of 130/80 mm Hg, which led to a new hypertension prevalence of 46%of U.S. adults. Despite the 12 percentage point increase in prevalencewith the lower diagnostic threshold, the 2017 ACC/AHA blood pres-sure guideline estimates that only an additional 2% of patients will be recommended anti hypertensive medications because the new guideline does not recommend that all patients with blood pressure readings of 130–139/80–89 mm Hg should receive drug therapy (Muntner 2018).

Hyper tension prevalence increases as patients age. Using the lower thresholdas defined by the 2017 ACC/AHA guide-lines, the prevalence of hypertension for patients 20–44 years of age is 30% inmen and 19% in women. This increases to 77% formen and 75% for women 65–74yearsofage (Whelt on 2018). Hypertension prevalence also differs on the basis of eth-nicity and sex. Overall, hyper tension is more prevalent in blacks, with an estimated prevalence of 59% and 56% in black men and women, respectively. White, Asian, and His panicmen have aprevalence of 47%, 45%, and 44%, respectively, and white, Asian, and His panic women have an estimated prevalence of 41%, 36%, and 42%, respectively (Whelton 2018). These numbers are based on the 2017 ACC/AHA guidelines and are higher than previous estimates because of the lower diagnostic threshold for hypertension in the new guidelines.

## CASE STUDY :

On February 26, 2020, Brazil experienced its first COVID-19 case, and by February 28th, the pandemic had severely damaged all of Brazil's states. Data from 57,768 adults over the age of 18 who had OBP and HBPM measurement between May 2017 and December 2020 at 719 centres spread across 26 of the 27 Brazilian states were used in two independent analyses. The first set of analyses looked at independent participants. who had one HBPM value available between January 1, 2019, and December 31, 2020 and were either untreated (n = 24,227) or treated with antihypertensive drugs (n = 27,699). The second round of analysis looked at 495 untreated people and 987 treated individuals whose blood pressure measurements were available from both before and after the pandemic. According to earlier descriptions, OBP was calculated as the average of two office readings, and HBPM as the average of three home readings taken in the morning and the evening for four consecutive days using validated devices (HEM-705CP, HEM-7113, HEM-7320, or HEM-9200T; Omron Health Care, Japan). High OBP was defined as having a systolic or diastolic blood pressure of at least 140 mmHg whereas high HBPM was defined as having a systolic or diastolic blood pressure of at least 135 mmHg. The Oswaldo Cruz University Hospital/PROCAPE Ethics Committee gave the protocol their seal of approval.

The mean, standard deviation, and proportion are used to represent continuous and categorical variables, respectively. Restrictive

International Journal of Pharmaceutical Research and Applications
Volume 8, Issue 4 July-Aug 2023, pp: 2552-2557 www.ijprajournal.com ISSN: 2249-7781

cubic splines were used to analyse individuals' OBP and HBPM control trajectories.

As well as choosing medications like calcium channel blockers and antihypertensive medicines. Angiotensin receptor blockers (ARBs) and ACE inhibitors (also known as angiotensin-converting enzyme inhibitors and angiotensin receptor inhibitors, respectively) were linked to a lower risk of COVID-19 hospitalisation compared to CCBs as well as a lower risk of intubation or death. where the risk variables of ACE inhibitor users were marginally lower than those of ARB users.

**SYMPTOMS:-**Most people with high blood pressure have no symptoms, even if blood pressure readings reach dangerously high levels. You can have high blood pressure for years without any symptoms.

**A few people with high blood pressure may have:**

- Headaches
- Shortness of breath
- Nosebleeds
- Dizziness
- Mental confusion
- Feeling like a heart attack
- Anxiety
- Chest pain

However, these symptoms aren't specific. They usually don't occur until high blood pressure has reached a severe or life-threatening stage.




**Figure No. 02**

**CLINICALGUIDELINEUPDATE:**

In2017,thelong-awaitedACC/AHAguidelinesfortheprevention,detection,evaluation,andmanagementofhighBPinadultswerepublished. These are the first comprehensive, evidence-basedguidelines forhypertension inthe UnitedStates.

**GUIDELINESFOR THE JOINT NATIONAL COMMITTEE:**

The Joint National Committee (JNC) published the first guidelines for the treatment of hypertension in the 1970s. These guidelines were developed primarily as a consensus of experts, not as a set of evidence-based recommendations. Nonetheless, the JNC guidelines remained the authoritative recommendation for hypertension until the National Heart, Lung, and Blood Institute (NHLBI) announced in 2013 that it was transferring responsibility for guideline development to other organizations. At that time, the ACC and AHA were responsible for leading the development of comprehensive, evidence-based hypertension guidelines. At the same time, the NHLBI released his JNC 8 Committee Recommendations. Despite the controversial release, the JNC 8 committee's purpose was to bridge the gap between JNC 7 and the new ACC/AHA guidelines that had been in development since JNC 7 was released in 2003. and many thought it was outdated. For example, JNC 7 recommended beta-blockers as an acceptable first-line treatment, but in 2017 most

International Journal of Pharmaceutical Research and Applications
Volume 8, Issue 4 July-Aug 2023, pp: 2552-2557 www.ijprajournal.com ISSN: 2249-7781

hypertension experts found no compelling indications, so beta-blockers are the other first-line treatment. I thought it was inferior to other antihypertensive drugs. The JNC 7 guidelines were a comprehensive expert consensus on the prevention, detection, assessment and treatment of hypertension in adults (Chobanian 2003) and the JNC 8 guidelines were a focused set of evidence-based recommendations. The JNC 8 committee selected three key questions to focus on in the updated guideline (box 1) and followed the same process for evaluating recommendations based on the available evidence as is the case for current guideline standards. Revised. What is unique about JNC 8 is the evidence included in that review, which formed the basis for its recommendations. Only randomized controlled clinical trials were reviewed. Meta-analyses, systematic reviews and epidemiological analyses were excluded. While the intention to limit the review to gold-standard evidence from randomized trials is understandable, this procedure has been criticized for not considering all the evidence.

**PROCESS:**

Increase the proportion of fruits, vegetables, whole grains, fish, nuts and legumes in your diet. The MIND diet lowers blood pressure and helps you lose weight.

Practice:Exercise improves blood flow. Aim for 30 minutes a day, 5 days a week. Reduce stress:Continuous psychological pressure can damage arterial walls. Use self-care strategies such as long walks, baths, therapy, journaling, and yoga to reduce stress.

Nicotine raises blood pressure, thickens the blood, and increases the buildup of plaque in arteries. Stopping the habit immediately reduces the risk of stroke. Maintain a  Losing just 10 pounds can have a big impact on your blood pressure.

You may need to control your blood pressure with drugs. Epidemiological evidence indicates that elevated blood pressure above 115/75 mm Hg increases the risk of vascular death (Lewington 2002). Blood pressure goals have been the subject of intense debate since 2013, when the JNC 8 recommendations became available. Although the JNC 8 recommendation to relax the SBP target from less than 140 mmHg to less than 150 mmHg for patients aged 60 years and older without diabetes or kidney disease has been criticized, the 2017 ACC/AHA hypertension guidelines call for stricter blood pressure. ing. pressure control. Below is a summary of clinical studies that have attempted to address this conundrum regarding optimal blood pressure targets. Of note, several well-conducted meta-analyses have explored this issue further (Bundy 2017; Reboussin 2017). A comprehensive discussion of this complex issue is beyondthe scope of this chapter.

**NEW DIAGNOSTIC CRITERIA AND DIAGNOSTIC CRITERIA:**

The 2017 guidelines lowered the diagnostic criteria for hypertension to 130/80 mm Hg from the decades-old standard of 140/90 mm Hg. The JNC 7 guidelines classify patients with blood pressure 130–139/80–89 mm Hg as “prehypertensive” based on cohort data showing the slope of increasing cardiovascular risk when blood pressure exceeds a threshold of 120 mm Hg. classified. As explained earlier, a lower diagnostic threshold for hypertension increases the prevalence of hypertension. The 2017 guidelines also updated the blood pressure category (see Table 1) and emphasized blood pressure.\

**RISK ASSESSMENT:**

The 2017 ACC/AHA guidelines recommend including cardiovascular risk estimates in blood pressure measurements to determine when antihypertensive medications should be initiated. Guidelines recommend that people at high cardiovascular risk start treatment when the SBP is 130 mm Hg or higher or the DBP is 80 mm Hg or higher. For individuals at low cardiovascular risk, taking antihypertensive medications is recommended if the SBP is ≥140 mm Hg or the DBP is ≥90 mm Hg (Whelton 2018). High CV risk is defined as a history of clinical CV disease or an estimated 10-year risk of atherosclerotic CV disease (ASCVD) of ≥10% according to the pooled cohort equation. Clinical CV disease is defined as coronary artery disease, heart failure, or stroke.

The inclusion of risk assessment in deciding when to start antihypertensive drugs derives in part from his SPRINT, which included cardiovascular risk assessment as part of the selection criteria. It was SPRINT investigators used the 10-year Framingham risk score to set a high CV risk threshold of 15%. This corresponds to a 10-year ASCVD risk of 6–7 according to the pooled cohort

International Journal of Pharmaceutical Research and Applications
Volume 8, Issue 4 July-Aug 2023, pp: 2552-2557 www.ijprajournal.com ISSN: 2249-7781

equation (Whelton 2018). The use of the pooled cohort equation is controversial because its role in estimating the risk of antihypertensive drug introduction has not been formally evaluated in clinical trials. Conversely, pooled cohort equations are becoming more common in clinical practice and are being integrated into some electronic medical records for efficient risk assessment. The pooled cohort equation has also been used to determine appropriate pharmacotherapy for dyslipidemia and has replaced Framingham as a modern CV risk estimator since 2014.

Evidence for evaluating pooled cohort equations in hypertension is emerging, but its use and thresholds to consider at different risk levels continue to be debated. Regardless of the method used to assess cardiovascular risk, physicians should be reminded that cardiovascular risk should be considered when treating hypertension because the benefit of treating hypertension is greatest in patients at highest cardiovascular risk. need to be aware (Muntner 2017).

## II. CONCLUSION

Out of 393 patients, 248 COVID-19 eligible patients were included, 169 (68.1%) of whom were men and 79 (31.9%) were women. In our study, 80 (32.3%) of 248 patients who had COVID-19 disease at 1 year's follow-up had newly developed hypertension. All patients' ages ranged from 51.16 to 12.71 years on average. We split 248 patients into two groups: those with hypertension (N=80) and those without (N=168). Radiologically, more hypertension patients than normotensive patients exhibited severe CT score severity (28.7 vs 14.9%; P0.02). According to the current study, males (75%) had a high prevalence of hypertension without any statistically significant difference.when COVID-19 was ill. In the hospital, patients were treated according on their severity. During their hospital stays, more patients in the hypertension group (73.8% vs. 39%; p0.0001) received steroid treatment.

## REFERENCE

[1]. Umemura S, Arima H, Arima S, Asayama K, Dohi Y, Hirooka Y, et al. The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2019) Hypertens Res: Off J Jpn Soc Hypertens. 2019;42:1235–481. doi: 10.1038/s41440-019-0284-9.

[2]. Yin J, Wang C, Song X, Li X, Miao M. Effects of Renin-Angiotensin system inhibitors on mortality and disease severity of COVID-19 patients: a meta-analysis of randomized controlled trials. Am J Hypertens. 2022;35:462–9. doi: 10.1093/ajh/hpac001.

[3]. Wrona M, Skrypnik D. New-onset diabetes mellitus, hypertension, Dyslipidaemia as Sequelae of COVID-19 infection-systematic review. Int J Environ Res Public Health. 2022;19:13280.

[4]. World Health Organization. Coronavirus Disease (COVID-2019) Situation Reports [EB/OL]. Available at: https://covid19.who.int/. Accessed March 22, 2021. [Google Scholar]

[5]. European Society of Hypertension Corona-virus Disease 19 Task Force. The corona-virus disease 2019 pandemic compromised routine care for hypertension: a survey conducted among excellence centers of the European Society of Hypertension. J Hypertens. 2021;39:190–5.

[6]. Ran J, Song Y, Zhuang Z, Han L, Zhao S, Cao P, et al. Blood pressure control and adverse outcomes of COVID-19 infection in patients with concomitant hypertension in Wuhan, China. Hypertens Res. 2020;43:1267–76.

[7]. Coronavirus COVID-19 Global Cases by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University. https://gisanddata.maps.arcgis.com/apps/opsdashboard/index.html#/bda7594.... Accessed 30 March 2020.

[8]. Phadke M, Saunik S. Rapid response: use of angiotensin receptor blockers such as Telmisartan, Losartsan in nCoV Wuhan Corona Virus infections—novel mode of treatment. Response to the emerging novel coronavirus outbreak. Br Med J 2020; 368:m406.

[9]. Wan Y, Shang J, Graham R, Baric RS, Li F. Receptor recognition by the novel coronavirus from Wuhan: an analysis based on decade-long structural studies of SARS coronavirus. J Virol 2020; 94:e00127-20.

[10]. Shibata S, Kobayashi K, Tanaka M, Asayama K, Yamamoto E, Nakagami H, et al. COVID-19 pandemic and

hypertension: an updated report from the Japanese Society of Hypertension project team on COVID-19. Hypertens Res. 2022:1–12.

[11]. World Health Organization (WHO). A clinical case definition of post COVID19 condition by a Delphi consensus, 6 October 2021. https://apps.who.int/iris/bitstream/handle/10665/345824/WHO-2019-nCoV-Post-COVID-19-condition-Clinical-case-definition-2021.1eng.pdf?sequence=1&isAllowed=y. Accessed 25 Dec 2022.

[12]. National Institute for Health. National Institute for Health and Care Excellence: Clinical Guidelines. COVID-19 rapid guideline: managing the long-term effects of COVID-19. London: National Institute for Health and Care Excellence (NICE); 2020. Copyright © NICE 2020.